Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
Ontosight® Newsletter Issue 3
Category: featured
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR). The parties will initially use Partex’ …
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership with Lupin, a global pharmaceutical company, to enhance drug discovery processes across multiple therapeutic areas. Leveraging advanced artificial intelligence technologies, Partex will empower Lupin’s Global Business Development and Licensing (BD&L) team with …
Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established contract research organisation, aimed at combining the strengths of Partex’s advanced AI & data services technology and Althea’s screening services and compounds. The immediate scope of this exciting partnership is to provide …
Innovative AI technology in oncology: Partex Group presents results from a pilot project
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the results of a pilot project carried out in cooperation with the German Cancer Society’s Working Group for Internal Oncology (AIO) under the leadership of AIO-Studien-gGmbH. The aim of the project was to investigate the feasibility …
Innovative AI technology in oncology: Partex Group presents results from a pilot project Read More »
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi’s out-licensing portfolio. Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion …
Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health data analysis, and AIO Studien gGmbH, with expertise in clinical studies and registries for oncology research, are jointly announcing the start of a pilot project as part of the AIO data hub initiative. This pilot …
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce their strategic partnership, aimed at revolutionizing the biopharma industry. By leveraging Partex’s proprietary AI (Artificial Intelligence) technology and Anavex’s innovative precision medicine drug development platform, we seek to enhance patient outcomes and reshape the …
AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary medical exchange, there are so-called tumor boards, in which the physicians discuss the treatment strategy. For this purpose, a large amount of medical data is available for each individual patient, which must be evaluated individually …
Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning (ML) to bring about new risk-transfer solutions for the life science industry. Eschborn, Germany/London, U.K., 27 July 2022Innoplexus AG is pleased to announce that an agreement for a strategic partnership with Innovatrix Capital Ltd. has …
